Quotient Wealth Partners LLC Sells 274 Shares of Danaher Co. (NYSE:DHR)

Quotient Wealth Partners LLC lessened its stake in shares of Danaher Co. (NYSE:DHR) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,369 shares of the conglomerate’s stock after selling 274 shares during the period. Quotient Wealth Partners LLC’s holdings in Danaher were worth $314,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Heck Capital Advisors LLC bought a new position in shares of Danaher in the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the 4th quarter worth $31,000. Golden State Wealth Management LLC acquired a new position in Danaher during the 4th quarter worth $31,000. Strategic Financial Concepts LLC bought a new stake in Danaher during the fourth quarter valued at about $31,000. Finally, Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter valued at about $39,000. 79.05% of the stock is owned by institutional investors.

Danaher Trading Down 1.5 %

DHR stock opened at $206.92 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The stock has a market capitalization of $149.45 billion, a price-to-earnings ratio of 39.19, a P/E/G ratio of 2.68 and a beta of 0.83. The business has a fifty day moving average price of $232.72 and a 200 day moving average price of $251.70. Danaher Co. has a fifty-two week low of $205.79 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the business earned $2.09 earnings per share. Analysts expect that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on DHR shares. JPMorgan Chase & Co. decreased their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Scotiabank began coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price objective on the stock. Barclays cut their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research report on Friday, December 13th. Finally, UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.